$APVO

$1.60▲ -0.6% YTD

8 SEC 13D/G filings tracked · Last updated Oct 26, 2026

Filing History

APVO ▼ -0.6% - Aptevo Therapeutics Inc.

CP $1.60▲ -0.6%Oct 26, 2026 · ThinkSabio Blog

$APVO - Aptevo Reports Mipletamig Combination Therapy Enabled 21% of Frontline AML Patients to Advance to Potentially Curative Stem Cell Transplant…

APVO ▼ -1.2% - Aptevo Therapeutics Inc.

CP $1.70▲ -1.2%Oct 14, 2026 · ThinkSabio Blog

$APVO - Aptevo to Showcase Multispecific Platform at SITC 2026 Annual Meeting…

APVO ▲ +4.5% - Aptevo Therapeutics Inc.

CP $1.87▲ +4.5%Oct 12, 2026 · ThinkSabio Blog

$APVO - Patent talk on name…

APVO ▲ +2.1% - Aptevo Therapeutics Inc.

CP $1.92▲ +2.1%Sep 24, 2026 · ThinkSabio Blog

$APVO - Aptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development…

APVO ▼ -12.7% - Aptevo Therapeutics Inc.

CP $2.26▲ -12.7%Sep 3, 2026 · ThinkSabio Blog

$APVO - Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML…

APVO ▲ +8.1% - Aptevo Therapeutics Inc.

CP $2.53▲ +8.1%Sep 2, 2026 · ThinkSabio Blog

$APVO vol…

APVO ▲ +8.1% - Aptevo Therapeutics Inc.

CP $2.53▲ +8.1%Sep 2, 2026 · ThinkSabio Blog

$APVO patent news…

$APVO SEC Filing Update (22-JUN-2026) | ThinkSabio - Stocks Simplified

$4.71▼ -49.84%Jun 22, 2026 · ThinkSabio Blog

SEC Filing Update: #APVO : $4.71 Sector: Healthcare | YTD: 🔽 -49.84% The SEC disclosed Today (22-JUN-2026) that NIOWAVE, INC. has Newly bought 151,723…